For in vitro diagnostic use. Nucleus Others Progesterone Receptor 1E2 CONFIRM IVD Breast CONFIRM anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody RTD000801 Rabbit 1E2 05278392001 CONFIRM ANTI-PR (1E2) 250 CONFIRM anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody 04015630972203 Reagents, kits 790-4296 250 tests Not Available true 05277990001 CONFIRM ANTI-PR (1E2) CONFIRM anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody 04015630972180 Reagents, kits 790-2223 50 tests Not Available true Le CONFIRM anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal (IgG) Primary Antibody est destiné à être utilisé en laboratoire pour la détection qualitative d’un antigène du récepteur de la progestérone (PR) dans des coupes de tissus fixés au formol et inclus en paraffine sur un automate de coloration VENTANA avec les kits de détection et les réactifs auxiliaires VENTANA. Le CONFIRM anti-PR (1E2) est dirigé contre un épitope présent sur le récepteur de la progestérone humain localisé dans le noyau des cellules normales et néoplasiques PR positives. Le CONFIRM anti-PR (1E2) est indiqué pour faciliter la prise en charge, le pronostic et la prédiction du résultat du traitement endocrinien du carcinome du sein.Ce produit doit être interprété par un anatomopathologiste qualifié, en complément d’examens histologiques, d’informations cliniques pertinentes et de contrôles adaptés.Utilisation uniquement sur ordonnance.Cet anticorps est conçu pour une utilisation en diagnostic in vitro (IVD). fr CONFIRM anti-PR (1E2) antibody binds to PR in formalin-fixed, paraffin embedded (FFPE) tissue sections. The specific antibody can be localized by either a biotin conjugated secondary antibody formulation that recognizes rabbit immunoglobulins, followed by the addition of a streptavidin horseradish peroxidase (HRP) conjugate (iVIEW DAB Detection Kit) or a secondary antibody-HRP conjugate (ultraView Universal DAB Detection Kit). The specific antibody-enzyme complex is then visualized with a precipitating enzyme reaction product.Clinical cases should be evaluated within the context of the performance of appropriate controls. Ventana Medical Systems, Inc. (Ventana) recommends the inclusion of a positive tissue control fixed and processed in the same manner as the patient specimen (for example, a weakly positive breast carcinoma or uterus). In addition to staining with CONFIRM anti-PR (1E2) antibody, a second slide should be stained with CONFIRM Negative Control Rabbit Ig. For the test to be considered valid, the positive control tissue should exhibit nuclear staining of the tumor cells or uterine glands and stroma. These components should be negative when stained with CONFIRM Negative Control Rabbit Ig. In addition, it is recommended that a negative tissue control slide (for example, a PR negative breast carcinoma) be included for every batch of samples processed and run on the BenchMark IHC/ISH instrument. This negative tissue control should be stained with CONFIRM anti-PR (1E2) antibody to ensure that the antigen enhancement and other pretreatment procedures did not create false positive staining. en